Items where Author is "Lawson, Kim"
Jump to: Article | Book Section
Number of items: 36.
Article
ERGISI, Mehmet, LAW, Alexander, CHAUDHARI, Nishant, TSATSARI, Stefania, LAWSON, Kim and JENNER, Christopher
(2023).
Effectiveness of topical gabapentin in the treatment of vulvodynia: a narrative synthesis.
Frontiers in Pain Research, 4: 1159268.
[Article]
LAWSON, Kim
(2023).
What is the progress of experimental drug development for fibromyalgia?
Expert Opinion on Investigational Drugs.
[Article]
FURNESS, Penelope, SHELTON, Tom, BERESFORD, Ruth, LAWSON, Kim, TAYLOR, Sophie and HAYWOOD-SMALL, Sarah
(2023).
Physiotherapy for fibromyalgia: a phenomenological study of patients’ experiences.
Journal of Pain Management, 15 (4).
[Article]
FURNESS, Penny, SHELTON, Tom, BERESFORD, Ruth, LAWSON, Kim, TAYLOR, Sophie and HAYWOOD-SMALL, Sarah
(2023).
Remote care for chronic pain: A qualitative evaluation with managers, practitioners and patients.
Journal of Pain Management, 15 (4).
[Article]
LAWSON, Kim
(2022).
Identification of the Involvement of Potassium Channels in Fibromyalgia.
Frontiers in Bioscience-Scholar, 14 (4): 29.
[Article]
PIRAGINE, Eugenia, CITI, Valentina, LAWSON, Kim, CALDERONE, Vincenzo and MARTELLI, Alma
(2022).
Potential Effects of Natural H2S-Donors in Hypertension Management.
Biomolecules, 12 (4): 581.
[Article]
PIRAGINE, Eugenia, CITI, Valentina, LAWSON, Kim, CALDERONE, Vincenzo and MARTELLI, Alma
(2022).
Potential effects of natural H 2 S-Donors in Hypertension Management.
Biomolecules, 12 (4): 581.
[Article]
LAWSON, Kim, SINGH, Attam, KANTSEDIKAS, Ilya, JENNER, Christopher Arthur and AUSTEN, Daniel Keith
(2021).
Flupirtine as a Potential Treatment for Fibromyalgia.
Journal of Exploratory Research in Pharmacology.
[Article]
TAYLOR, Sophie, FURNESS, Penny, ASHE, Simon, HAYWOOD-SMALL, Sarah and LAWSON, Kim
(2021).
Comorbid Conditions, Mental Health and Cognitive Functions in Adults with Fibromyalgia.
Western Journal of Nursing Research, 43 (2), 115-122.
[Article]
LAWSON, Kim
(2020).
Sleep Dysfunction in Fibromyalgia and Therapeutic Approach Options.
OBM Neurobiology, 4 (1), p. 16.
[Article]
LAWSON, Kim
(2019).
Is there a role for melatonin in fibromyalgia?
AIMS Molecular Science, 6 (4), 73-86.
[Article]
LAWSON, Kim
(2019).
Pharmacology and clinical applications of flupirtine: Current and future options.
World journal of pharmacology, 8 (1), 1-13.
[Article]
LAWSON, Kim
(2018).
Kv7 channels a potential therapeutic target in fibromyalgia: A hypothesis.
World Journal of Pharmacology, 7 (1), 1-9.
[Article]
TAYLOR, Sophie, STEER, Michael, ASHE, Simon, FURNESS, Penny, HAYWOOD-SMALL, Sarah and LAWSON, Kim
(2018).
Patients' perspective of the effectiveness and acceptability of pharmacological and non-pharmacological treatments of fibromyalgia.
Scandinavian Journal of Pain.
[Article]
FURNESS, Penny, VOGT, Katharina, ASHE, Simon, TAYLOR, Sophie, HAYWOOD-SMALL, Sarah and LAWSON, Kim
(2018).
What causes Fibromyalgia? An online survey of patient perspectives.
Health Psychology Open, 5 (2).
[Article]
LAWSON, Kim
(2018).
Flupirtine is an effective analgesic: is the associated rare liver injury a limiting factor to its use?
Anesthesia and Analgesia.
[Article]
ASHE, Simon, FURNESS, Penny, TAYLOR, Sophie, HAYWOOD-SMALL, Sarah and LAWSON, Kim
(2017).
A qualitative exploration of the experiences of living with and being treated for fibromyalgia.
Health Psychology Open, 4 (2), 1-12.
[Article]
LAWSON, Kim
(2017).
A brief review of the pharmacology of amitriptyline and clinical outcomes in treating fibromyalgia.
Biomedicines, 5 (2), p. 24.
[Article]
LAWSON, Kim
(2017).
Emerging pharmacological strategies for the treatment of
fibromyalgia.
World Journal of Pharmacology, 6 (1), 1-10.
[Article]
ASHE, Simon, FURNESS, Penny, TAYLOR, Sophie, HAYWOOD-SMALL, Sarah and LAWSON, Kim
(2016).
"Not all in my head": a qualitative exploration of living with fibromyalgia and its treatments (Oral presentation).
The European Health Psychologist, 18 (Supp), p. 695.
[Article]
LAWSON, Kim
(2016).
Fibromyalgia pathogenesis provides drug target clues.
Drug Target Review, 3, 45-49.
[Article]
LAWSON, Kim
(2016).
Potential drug therapies for the treatment of fibromyalgia.
Expert opinion on investigational drugs, 1-11.
[Article]
LAWSON, Kim
(2014).
Clinical trials for patients with fibromyalgia syndrome.
Clinical & Experimental Pharmacology, 04 (05).
[Article]
MARTELLI, A., TESTAI, L., BRESCHI, M.C., LAWSON, Kim, MCKAY, Neil, MICELI, F., TAGLIALATELA, M. and CALDERONE, V.
(2013).
Vasorelaxation by hydrogen sulphide involves activation of Kv7 potassium channels.
Pharmacological Research, 70 (1), 27-34.
[Article]
BEARD, S M, ROSKELL, N, LE, T K, ZHAO, Y, COLEMAN, A, ANG, D and LAWSON, Kim
(2011).
Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States.
Journal of medical economics.
[Article]
VAHABI, B, LAWSON, Kim, MCKAY, Neil and SELLERS, Donna
(2011).
Phasic activity of urinary bladder smooth muscle in the streptozotocin-induced diabetic rat: effect of potassium channel modulators.
European Journal of Pharmacology, 660 (2-3), 431-437.
[Article]
PUTTINI, P. Sarzi, HĂ„USER, W., LAWSON, Kim and SPROTT, H.
(2009).
11 Topical Seminar Summary: FIBROMYALGIA SYNDROME.
European Journal of Pain, 13, S5-S6.
[Article]
VAHABI, B, LAWSON, Kim, MCKAY, Neil and SELLERS, Donna
(2009).
Cholinergic modulation of spontaneous activity in bladder strips from the diabetic rat : effect of the mucosa.
European Eurology Supplements, 8 (4), p. 177.
[Article]
VAHABI, B., MCKAY, Neil, LAWSON, Kim and SELLERS, Donna
(2008).
Identification of C-Kit positive cells in rat urinary bladder and characterization of their functional role in spontaneous activity in control and diabetic bladders.
European Eurology Supplements, 7 (3), p. 181.
[Article]
SELLERS, Donna, MCKAY, Neil and LAWSON, Kim
(2008).
Inhibitory effect of cromakalim on muscarinic receptor-stimulated spontaneous activity in diabetic rat bladder.
Fundamental & Clinical Pharmacology, 22 (Suppl), p34.
[Article]
LAWSON, Kim
(2007).
Are complex therapies required as pharmacological treatments of fibromyalgia?
Future Rheumatology, 2 (6), 599-605.
[Article]
LAWSON, Kim
(2006).
Emerging pharmacological therapies for fibromyalgia.
Current Opinion in Investigational Drugs, 7 (7), 631-636.
[Article]
LAWSON, Kim
(2006).
Potassium channels as targets for the management of pain.
Central Nervous System Agents in Medicinal Chemistry, 6 (2), 119-128.
[Article]
LAWSON, Kim
(2002).
Tricyclic antidepressants and fibromyalgia: what is the mechanism of action?
Expert opinion on investigational drugs, 11 (10), 1437-1445.
[Article]
LAWSON, Kim and DUNNE, Mark J.
(2001).
Peripheral channelopathies as targets for potassium channel openers.
Expert opinion on investigational drugs, 10 (7), 1345-1359.
[Article]
Book Section
MCKAY, Neil, KIRBY, R W and LAWSON, Kim
(2008).
Rubidium efflux as a tool for the pharmacological characterisation of compounds with BK channel opening properties.
In: LIPPIAT, Jonathan D, (ed.)
Potassium channels : methods and protocols.
Methods in Molecular Biology
(491).
Humana Press, 267-277.
[Book Section]